Evaluation Of HUK in Acute Stroke Patients: MRS and CTP
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
Background: Acute ischemic stroke (AIS) is a leading cause of morbidity and mortality
worldwide. Human urinary kallidinogenase (HUK), a glycoprotein extracted from male urine
currently used in China for enhancing cerebral perfusion5, plays a neuroprotective role
including promoting angiogenesis, enhancing cerebral perfusion and suppressing the
inflammatory response in animals and in patients with respect to regulating the
kallikrein-kinin system. In previous clinical research, neurological function scores and
cerebral perfusion scans were largely used to evaluate the efficiency of HUK. However, the
mechanisms of Further well-conducted, randomized controlled studies using HUK are currently
lacking.
Objective: To assess the Human urinary kallidinogenase effects on brain metabolite and
cerebral perfusion changes using magnetic resonance spectroscopy and CT perfusion in patients
with AIS.
Methods: The investigators plan to do a single-centre randomized, double-blind, controlled
trial in which ischemic stroke patients will be randomized to treatment with either HUK or
regular treatment within 72 hours of symptom onset. The study includes two MRS and two CTP
scannings (before and after 2 week treatment) for all randomized subjects.
The endpoints will include improvement of the NIH Stroke Scale (NIHSS) score from baseline,
modified Rankin scale (mRS) score and Barthel index at 14 days.
EvHUKMRS will test the following hypotheses:
1. HUK enhanced N-acetylaspartate (NAA) and cerebral blood flow (CBF) 14 days after
treatment compared with control group.
2. HUK group compared to control group when administered 72 hours after onset of AIS
improves recovery and functional outcome as assessed by improvement of NIHSS score , mRS
score and BI score on day 14 post-stroke.
A positive result will have a significant impact in the management of AIS and pave the way
for future studies aimed at finding the optimal dose and formulation of HUK for treating
acute ischemic stroke.